Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Regulus, Rutgers, Monsanto, and More


Title: Oligomeric Compounds and Compositions for Use in Modulation of Small, Non-coding RNAs

Patent Number: 8,697,663

Filed: Dec. 30, 2008

Lead Inventor: Frank Bennett, Regulus Therapeutics

Title: Cyclodextrin-modified Polyamines for Delivery of Therapeutics Molecules

Patent Number: 8,697,667

Filed: Oct. 11, 2011

Lead Inventor: Ki-Bum Lee, Rutgers University

Title: miRNA-regulated Differentiation-dependent Self-delecting Cassette

Patent Number: 8,697,851

Filed: Dec. 3, 2012

Lead Inventor: David Frendewey, Regeneron Pharmaceuticals

Title: microRNA and Methods for Inhibiting the Same

Patent Number: 8,697,859

Filed: Jan. 18, 2013

Lead Inventor: Markus Stoffel, Rockefeller University

Title: Temporal Regulation of Gene Expression by microRNAs

Patent Number: 8,697,949

Filed: June 26, 2008

Lead Inventor: Edwards Allen, Monsanto

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.